Open innovation: A paradigm shift in pharma R&D?
Journal
Drug Discovery Today
ISSN
1359-6446
Type
journal article
Date Issued
2022-09
Author(s)
Abstract (De)
•
We analyzed 21 leading research-based pharmaceutical companies by global sales 2019 regarding their inbound R&D activities between 2015 and 2019.
•
Over the last decade open innovation (OI) has found its way into and is a widely used R&D model of the research-based pharmaceutical industry.
•
The depth and breadth of implementation differs greatly across major industry players: While four pharmaceutical companies (Novartis, Otsuka, Gilead, and Allergan) rely more on traditional R&D concepts, the vast majority (15 out of 21 companies) also uses network-based OI models to supplement R&D. And two companies (Bayer and AstraZeneca) have opened their R&D into ecosystem-enabled.
We analyzed 21 leading research-based pharmaceutical companies by global sales 2019 regarding their inbound R&D activities between 2015 and 2019.
•
Over the last decade open innovation (OI) has found its way into and is a widely used R&D model of the research-based pharmaceutical industry.
•
The depth and breadth of implementation differs greatly across major industry players: While four pharmaceutical companies (Novartis, Otsuka, Gilead, and Allergan) rely more on traditional R&D concepts, the vast majority (15 out of 21 companies) also uses network-based OI models to supplement R&D. And two companies (Bayer and AstraZeneca) have opened their R&D into ecosystem-enabled.
Language
English
HSG Classification
contribution to scientific community
HSG Profile Area
SoM - Business Innovation
Refereed
Yes
Publisher
Elsevier Science
Volume
Vol 27
Number
9
Start page
2395
End page
2405
Subject(s)
Division(s)
Eprints ID
267634
File(s)![Thumbnail Image]()
Loading...
open.access
Name
22 DDT OI in pharma.pdf
Size
400.01 KB
Format
Adobe PDF
Checksum (MD5)
11899abc60614259446c8dd20f418b1c